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Storing vaccine at temperatures either too hot or 
too cold, can have a 
devastating effect on product 
efficacy.  Additionally, it is 
impossible to tell if vaccine has 
been exposed to temperatures 
outside the intended range just 
by looking at it.  Temperature 
monitoring is a key component to safely storing 
vaccine. 
Temperatures should be monitored twice a day, 
even if alarm monitors and continuous graphing 
thermometers are used.  Some of the most 
common mistakes in vaccine storage include not 
recording temperatures twice daily, not taking 
action if the temperature falls outside the 
allowable range, and not designating more than 
one person in each office to monitor 
temperatures.   
Refrigerator temperatures must be between 35o 
and 46o F (2o - 8o C). Refrigerator temperatures 
naturally fluctuate, so aim for an average daily 
temperature of 40o F.  Freezer temperatures must 
be maintained at 5o F or less (-15o C or less).   
Recording temperatures twice daily is the 
standard protocol for vaccine storage and is the 
best way to identify when a unit is not maintaining 
proper temperature ranges.  The Immunization 
Program has temperature charts available on our 
Web page or at the Health Protection Clearing 
House at 1-888-398-9696 (see page 3 for Web 
address).   
Temperature logs should be kept for at least 3 
years (some facilities may require logs be kept 
longer) to identify on-going problems or when a 
unit may need to be replaced.  Continued on 
page 3. 
Volume 1, Issue 3 
It’s Not to Late to Vaccinate Against Influenza 
Influenza is a serious disease that attacks people 
of every stage of life.  In the United States, even 
in an average year, influenza 
causes 36,000 deaths (mostly 
among those aged 65 years or 
older) and more than 200,000 
hospitalizations.  The "flu 
season" in Iowa generally peaks 
in February each year.   An 
annual influenza vaccine (either 
the flu shot or the nasal-spray 
flu vaccine) is the best way to 
reduce the chances of getting 
and spreading the virus. 
Vaccinating against influenza 
after the month of November will 
still benefit  patients, even if flu 
is present in the community.  
Vaccine should continue to be offered to 
unvaccinated people throughout the “flu season” 
(through March) as long as vaccine remains 
available.  Once vaccinated, it takes only about 
two weeks to make 
protective antibodies 
against the influenza virus. 
Influenza vaccine contains 
three virus strains: two 
type A viruses and one 
type B virus.  The exact 
vaccine composition 
changes year to year.  
Inactivated influenza 
vaccine, “the flu shot,” 
contains killed viruses.  In 
contrast, the nasal spray 
contains live attenuated 
viruses. See page 4 for a 
table describing the 
approved influenza vaccines for different age 
groups.   
When determining influenza vaccine     
dosing consider the following: 
• Age of the recipient.  Dose of vaccine is 
dependent on the recipient's age, a child 6 
months through 35 months should receive 
0.25 ml, persons 36 months (3 year old) and 
older should receive 0.5 ml. 
• Previously unvaccinated children.  Children 
6 months through 8 years of age, should 
receive 2 doses of vaccine (inactivated one 
month apart, live-attenuated 6 weeks apart).    
• Vaccine manufacturer.  Brands are licensed 
for specific ages (refer to the chart on page 4).   
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In this article the CDC answers commonly 
asked questions regarding hepatitis B and 
Health Care Workers (HCW).  This is re-
printed, in part, from the Immunization 
Action Coalition.  You can view and print the 
entire article at the following Web page:  
http://www.immunize.org/catg.d/2109hcw.htm 
If a HCW had one dose only of hepatitis 
B vaccine 4 months ago, should the 
series be restarted? 
No. The hepatitis B vaccine series should 
not be restarted when doses are delayed; 
rather, the series should be continued from 
where it stopped. The HCW should receive 
the second dose of vaccine now and the 
third dose at least 8 weeks later. There 
needs to be at least 16 weeks between the 
first and the third doses and at least 8 
weeks between the second and third doses 
of vaccine. 
Which HCWs need serologic testing after 
receiving 3 doses of hepatitis B vaccine? 
All HCWs who have a reasonable risk of 
exposure to blood or body fluids containing 
blood (e.g., HCWs with direct patient 
contact, HCWs who have the risk of 
needlestick or sharps injury, laboratory 
workers who draw or test blood) should 
have postvaccination testing for antibody to 
hepatitis B surface antigen (anti-HBs). 
Postvaccination testing should be done 1–2 
months after the last dose of vaccine. 
What should be done if a HCW's 
postvaccination anti-HBs test is negative 
1-2 months after the last dose of 
vaccine? 
Repeat the 3-dose series and test for anti-
HBs 1–2 months after the last dose of 
vaccine. If the HCW is still negative after a 
second vaccine series, the HCW is 
considered a non-responder to hepatitis B 
vaccination. HCWs who do not respond to 
vaccination should be tested for HBsAg to 
determine if they have chronic HBV 
infection. If the HBsAg test is positive, the 
person should receive appropriate 
counseling and medical management. 
Persons who test negative for HBsAg 
should be considered susceptible to HBV 
infection and should be counseled about 
precautions to prevent HBV infection and 
the need to obtain hepatitis B immune 
globulin (HBIG) prophylaxis for any known 
or likely exposure to HBsAg-positive blood. 
How often should I test HCWs after 
they've received the hepatitis B vaccine 
series to make sure they're protected? 
For immune competent HCWs, periodic 
testing or periodic boosting is not needed. 
Postvaccination testing (anti-HBs) should 
be done 1–2 months after the last dose of 
hepatitis B vaccine. If adequate anti-HBs (at 
least 10 mIU/mL) is present, nothing more 
needs to be done. If postvaccination testing 
is less than 10 mIU/mL, the vaccine series 
should be repeated and anti-HBs testing 
done, 1-2 months after the last 
dose of the second series. This 
information should be recorded 
in the HCW's employee health 
record. 
Should a HCW who performs 
invasive procedures and who 
once had a positive anti-HBs 
result be revaccinated if the 
anti-HBs titer is rechecked 
and is less than 10 mIU/mL? 
No. Immune competent persons 
known to have responded to 
hepatitis B vaccination do not 
require additional passive or 
active immunization. Postvaccination 
testing should be done 1–2 months after 
the original vaccine series is completed. In 
this scenario, the initial postvaccination 
testing showed that the HCW was 
protected. Substantial evidence suggests 
that adults who respond to hepatitis B 
vaccination (anti-HBs of at least 10 
mIU/mL) are protected from chronic HBV 
infection for as long as 23 years, even if 
there is no detectable anti-HBs currently. 
Only immunocompromised persons (e.g., 
hemodialysis patients, some HIV-positive 
persons) need to have anti-HBs testing and 
booster doses of vaccine to maintain their 
protective anti-HBs concentrations of at 
least 10 mIU/mL. 
If HCWs received hepatitis B vaccination 
in the past and were not tested for 
immunity, should they be tested now? 
No. In this scenario, a HCW does not need 
to be tested unless she/he has an 
exposure. If an exposure occurs, refer to 
the postexposure guidelines in Table 1 on 
page 6. 
How should a vaccinated HCW with an 
unknown anti-HBs response be 
managed if they have a percutaneous or 
mucosal exposure to blood or body 
fluids from an HBsAg-positive source? 
This person should be tested for anti-HBs 
as soon as possible after exposure. If the 
anti-HBs concentration is at least 10 
mIU/mL, no further treatment is needed. If 
the anti-HBs concentration is less than 10 
mIU/mL, HBIG and one dose of hepatitis B 
vaccine should be 
administered. Prior 
to administering 
the HBIG and 
vaccine, blood 
should be drawn 
for a baseline 
HBsAg test. 
Subsequently, in 
3–6 months, an 
additional anti-HBs 
and an HBsAg test 
should be 
performed. If the 
HBsAg is positive, 
the person is 
infected and should be referred for medical 
evaluation. If the anti-HBs result is at least 
10 mIU/mL, the person is seroprotected. It 
is necessary to do postvaccination testing 
later than the usual recommended time 
frame because anti-HBs from HBIG might 
be detected if testing is done any earlier. 
The postvaccination test result should be 
recorded in the person's health record. 
Several physicians in our group have no 
documentation showing they received 
hepatitis B vaccine. They are relatively 
sure, however, that they received the 
doses many years ago. What do we do 
now?  
Because there is no documentation of 
vaccination, the 3-dose vaccination series 
should be administered and postvaccination 
testing should be performed 1–2 months 
after the third dose of vaccine. There is no 
harm in receiving extra doses of vaccine.   
Continued on page 6
Hepatitis B and the Health Care Worker 
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it consistently maintains the appropriate 
vaccine temperatures.   
If improperly stored vaccines were adminis-
tered to patients, revaccination may be neces-
sary.  “If mishandled or expired vaccines are  
administered inadvertently, they should not be 
counted as valid doses and should be re-
peated, unless serologic testing indicates a 
response to the vaccine.” (MMWR Vol. 51/RR-
2, February 8, 2002)  Please contact the Im-
munization Program (below) for guidelines and 
resources regarding revaccina-
tion efforts.   
It is important to train all staff 
regarding vaccine storage and 
handling.  Staff should be famil-
iar with all aspects of vaccine 
storage and handling, including 
knowing how to handle vaccines 
when they arrive, how to properly 
record refrigerator and freezer 
temperatures, and what to do in 
case of an equipment problem or 
power outage.  A back up person 
should be designated to review 
the temperature logs weekly.   
Recommendations for handling 
and storage of selected biologics 
are summarized in several ar-
eas:  Epidemiology of Vaccine 
Preventable Diseases (Pink 
Book) Appendix C, package 
It is important to have a designated plan in 
the event of improper vaccine storage and 
handling.  The Immunization Program has 
an Emergency Response Plan Worksheet 
to assist in developing action plans in the 
event of an out of range temperature.  The 
document is available on the Immunization 
Program Web page at: 
http://www.idph.state.ia.us/adper/immunization.asp.    
If improper vaccine storage and handling is 
identified the following action steps should 
be implemented.  
1. Immediately notify a supervisor, 
mark the vaccine that is compromised, 
do not allow it to be administered, and 
store it in another unit at the appropri-
ate temperature.   
2. Call the manufacture to determine 
what should be done with the effected 
vaccine.   
3. Check the condition of the refrigera-
tor/freezer for problems.  Are the seals 
tight? Is there excessive lint or dust on 
the coils?  
4. After you have made the necessary 
adjustments or a trained technician 
has identified and fixed the problem, 
document the date, time, tempera-
ture, what the problem was, the action 
you took, and the results of this action. 
Do not replace vaccine in the unit until 
inserts for each product, Centers for Disease 
Control and Prevention publication titled Vac-
cine Management, and a Web-based toolkit 
available at 
http://www2a.cdc.gov/nip/isd/shtoolkit/splash.html 
Health care providers are encouraged to 
review temperature monitoring procedures 
and review and exercise emergency vaccine 
recovery plans.  Contact Don Callaghan, 
Immunization Program manager, with ques-
tions at 1-800-831-6293, ext. 1. 
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Vaccine Storage and Handling, continued 
Top 10 Storage and Handling Errors 
1. Designating only one person in the office to be responsible 
for storage and handling of vaccines, instead of a minimum of 
two. 
2. Recording temperatures only once per day and recording 
temperatures for only the refrigerator or freezer. 
3. Documenting out-of-range temperatures on vaccine tempera-
ture logs and not taking action. 
4. Throwing away temperature logs at the end of every month. 
5. Storing vaccine in the refrigerator in a manner that may 
inappropriately affect its temperature. 
6. Storing frozen vaccines in a dorm-style refrigerator. 
7. Inadvertently leaving the refrigerator or freezer door open or 
having inadequate seals. 
8. Discarding multi-dose vials 30 days after they are opened. 
9. Not having emergency plans for a power outage or natural 
disaster. 
10. Storing food and drinks in the vaccine refrigerator. 
VFC Vaccine Ordering  
ProQuad or MMR and Varicella 
In June 2006, the Advisory 
Committee on Immunization 
Practices recommended two doses 
of varicella vaccine for children, 
adolescents, and adults who 
previously had only one dose.  The 
second dose is designed to more 
closely mirror natural disease and to 
further improve protection from 
varicella disease.  
 It is recommended that health care 
providers use the MMR/varicella 
combination 
vaccine (ProQuad) 
when applicable.  
The Iowa 
Vaccines for Children Program is 
requesting providers assess their 
inventory of MMR and varicella vaccine 
and assure an appropriate vaccine 
inventory level is maintained before 
placing an order for ProQuad.  With the 
increased cost of vaccines and the 
addition of new vaccines, it is imperative 
that vaccine is not wasted.   
Iowa Immunization         
Conference  
SAVE THE DATE 
The 2007 Immunization Conference will be 
held June 7, 2007, at the  Hy-Vee Conference 
Center in West Des Moines. 
This is the statewide immunization conference 
sponsored by the Iowa Department of Public 
Health.  Speakers include Dr. William Atkinson 
from CDC, Dr. Paul Offit from the Children’s 
Hospital of Philadelphia, and Patricia Stinchfield, 
RN, MS, CPNP from the Children’s Hospitals & 
Clinics, St. Paul, Minnesota.  More information to 
come - mark your calendars for June 7, 2007! 
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It’s Not to Late to Vaccinate Against Influenza, continued 
Influenza outbreaks occur throughout the general 
population as well as in health care settings.  
Health care providers can reduce the transmission 
of influenza by receiving annual influenza vaccine.  
The Healthcare Infection Control Practices Advisory 
Committee and the Advisory Committee on Immu-
nization Practices recommends all health care 
workers, including those in acute care hospitals, 
nursing homes, skilled nursing facilities, physician's 
offices, urgent care centers, and outpatient clinics, 
and persons who provide home health care and 
emergency medical services be vaccinated annu-
ally against influenza.  Influenza vaccination benefits health care workers, family 
members, coworkers and their patients.  The Immunization Program has posters 
and paycheck stuffers available to promote influenza vaccination among health 
care workers.  These products are available online at 
http://www.idph.state.ia.us/adper/flu_healthcare_provide.asp or by contacting the 
Health Protection Clearinghouse at 1-888-398-9696.  Get your influenza vaccine 
today, everyone is counting on you!  
Approved Influenza Vaccines for Different Age Groups – United States, 2006-2007 season  
Source:  MMWR, June 28, 2006/ Vol.55 
Vaccine* Trade name Manufacturer Dose/Presentation 
Thimerosal 
mercury con-
tent (mcg Hg/0.5-mL 
dose) 
Age Group No. of Doses Route 
Inactivated               
Trivalent Inactivated 
Vaccine (TIV) Fluzone sanofipastuer 0.25-mL prefilled syringe 0 6-35 mos 1 or 2† IM$ 
      0.5-mL prefilled syringe 0 36 months or greater 1 or 2† IM$ 
      0.5-mL Vial 0 36 months or greater 1 or 2† IM$ 
      5.0-mL multi-dose vial 25 6 months or greater 1 or 2† IM$ 
TIV Fluvirin Novartis Vaccine 0.5-mL prefilled syringe <1.0 4 yrs or greater 1 or 2† IM$ 
      5.0-mL multi-dose vial 24.5 4 yrs or greater 1 or 2† IM$ 
TIV FLUARIX GlaxoSmithKline 0.5-mL prefilled syringe <1.0 18 yrs or greater 1 IM$ 
Live, Attenuated               
LAIV FluMist MedImmue 0.5-mL Sprayer 0 5-49 yrs 1 or 2¶ Intranasal** 
* A 0.5-mL dose contains 15 mcg each of A/New Caledonia/20/1999 (H1N1)-like, A/Wisconsin/67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like antigens. For the A/Wisconsin/67/2005 (H3N2)-like 
antigen, manufactures may use the antigenically equivalent A/Hiroshima/52/2005 virus, and for the B/Malaysia/2506/2004-like antigen, manufactures may use the antigenically equivalent B/Ohio/1/2005 
virus.  
† Two doses administered at least 1 month apart are recommended for children aged 6 months through 8 years of age who are receiving influenza vaccine for the first time.  
$ For adults and older children, the recommended site of vaccination is the deltoid muscle.  The preferred site for infants and young children is the anterolateral aspect of the thigh.   
¶ Two doses administered at least 6 weeks apart are recommended for children ages 5 through 8 years of age who are receiving influenza vaccine for the first time.  
Health Care Worker Influenza Vaccination  News You Can Use: 
Useful Web Sites for  
Immunization Providers 
 
Centers for Disease Control and Prevention  
National Immunization Program    
www.cdc.gov/nip   
 
The Immunization Action Coalition 
www.immunize.org  
 
Children’s Hospital of Philadelphia   
www.vaccine.chop.edu  
 
American Academy of Pediatrics  
www.aap.org        
 
Iowa Immunization Program 
www.idph.state.ia.us/adper/immunization.asp 
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Hib – Who Needs a Booster?  
In the United States, two single antigen 
Haemophilus influenza type B (Hib) 
vaccines are available, ActHib and Ped-
vaxHib.  These two vaccines have dif-
ferent requirements that may create 
confusion.   
ActHib, manufactured by Sanofi, 3 
dose primary series (2, 4, & 6 months of 
age) with a booster at 12-15 months. 
PedvaxHib, manufactured by Merck, 
(PedvaxHib is in the combination Com-
vax-PedvaxHib/Hepatitis B), 2 dose 
primary series (2 & 4 months of age) 
with a booster at 12-15 months. 
The number of doses in the primary 
series varies depending upon the 
type/brand of vaccine used.  If brands 
are changed during the vaccine series, 
a 3 dose primary series is required.  A 
booster dose is recommended at 
12-15 months of age regardless of 
which vaccine is used for the pri-
mary series. 
Children starting vaccination late may 
not need the entire 3 or 4 dose series of 
vaccine.  The number of doses of vac-
cine recommended for the child de-
pends on their current age and the age 
when they received the last dose of 
vaccine.  All children 15-59 months of age 
should receive at least 1 dose.  Children 15-59 
months of age who have an incomplete Hib 
vaccination history, including those who are 
unvaccinated, should receive a single dose of 
any Hib vaccine.  Hib vaccine is not routinely 
recommended for persons 5 years of age or 
older unless there are underlying conditions 
such as sickle cell disease, anatomic asplenia, 
and immunosuppression from chemotherapy or 
HIV (see page 120 of the 9th edition of Epide-
miology of Vaccine Preventable Diseases “Pink 
Book”). 
There are 2 combination Hib vaccines.  TriHibit 
manufactured by Sanofi (ActHib reconstituted 
with Tripedia DTaP) is licensed for the 4th dose 
of the DTaP & Hib series only.  It may be used 
as the booster dose of Hib after 12 months of 
age following any Hib series.  TriHibit should 
not be used if the child has received no prior 
Hib doses. 
Comvax manufactured by Merck (Pedvax Hib & 
Hepatitis B combination) used after 6 weeks of 
age when both antigens are indicated.  Usually 
given at 2 and 4 months with a booster at 12-15 
months of age. 
If you have questions regarding spacing of Hib 
vaccine or booster doses, please contact Terri 
in the Immunization Program at 1-800-831-
6293, ext. 1.  
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 Hib Vaccine Q and A: 
Q:  If an infant received one dose of Hib at 5 
months and another at 15 months, does he/she 
need any more doses? 
A:  No.  If a child receives a dose of Hib vaccine 
at 15 months of age or older, he or she does not 
need any further doses regardless of the number 
of doses received before 15 months of age. 
Q:  Since the booster dose of Hib can be given 
at 12-15 months, is it still necessary to “boost” 
two months later if the first dose was given at 12-
14 months? 
A:  If the child received a primary series (2 or 3 
doses) of Hib vaccine in the first year of life, then 
the final (booster) dose of the series may be 
given as early as 12 months, provided at least 2 
months have passed since the last dose.  An 
unvaccinated 12-14 month old child should re-
ceive one dose as a primary series, and a 
booster dose 2 months later.  Unvaccinated 
children 15-59 months of age need only a single 
dose of any licensed Hib vaccine. 
 Q:  A 4-year old received dose #3 of Hib at 6 
months of age.  Does the child need dose #4? 
A:  Yes.  All children less than 5 years old need 
at least one dose of Hib vaccine on or after the 
first birthday.  The last dose should be separated 
from the previous dose by at least 2 months. 
During the holiday season, the Immunization  
Program will NOT ship vaccine from     
December 21st through January 5th.   
In addition, vaccine orders will NOT be distrib-
uted during periods of extreme cold and 
snow.  It is of the utmost importance that vac-
cine wastage is minimized and vaccine re-
mains efficacious and viable.   
Pay close attention to 
your vaccine inventory throughout the win-
ter.  Please remember to return coolers 
upon receipt of vaccine, using the enclosed 
postage paid label. 
ATTENTION  
HOLIDAY VACCINE 
We Want Your Bright Ideas! 
 
We are looking for creative ideas that you use 
in practice to assure proper storage and han-
dling of vaccine.   
We would like you to send ideas that have 
worked well for your clinic or agency or ideas 
of techniques, products, or support the Immu-
nization Program may provide to assist with 
appropriate vaccine storage and handling.  
Please send comments and ideas to Bridget 
Konz at bkonz@idph.state.ia.us or fax them 
to 1-800-831-6292.   
We hope to learn from you.  Ideas will be shared in future  
issues of the newsletter.  Don’t be shy, we want your bright ideas! 
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Long-term immunity has been shown only for 
persons attaining an adequate anti-HBs result 
of at least 10 mIU/mL after a 3-dose 
vaccination series. The most direct way to 
deal with this is to vaccinate the HCW with 
the 3-dose series of hepatitis B vaccine; test 
for anti-HBs in 1–2 months and document the 
result in the HCW's employee health record. 
An adequate anti-HBs result from a 
documented 3-dose vaccine series would 
assure not only seroprotection, but long-term 
protection, as well. 
Of course, it is possible that the HCW has an 
anti-HBs result of greater than 10 mIU/mL 
because of an HBV infection in the past. If 
this is of concern, a total anti-HBc test could 
be performed to discern this (a positive result 
indicates a history of HBV infection at some 
undefined period in time). 
Care should always be taken to document 
vaccine lot, date, manufacturer, route, and 
vaccine dosages. Postvaccination testing 
results should also be documented, including 
the date testing was performed. All 
organizations (e.g., hospitals, clinics) should 
develop policies or guidelines to assure valid 
hepatitis B immunization.  
A healthcare worker (HCW) thinks she had 3 
doses of hepatitis B vaccine in the past but 
has no documentation of receiving those 
doses. Before reading the recommendations 
to revaccinate her, we obtained an anti-HBs 
titer and the result was greater than 10 
mIU/mL. With this lab result, can't we 
assume she is immune? 
A positive anti-HBs indicates that the 
vaccinated person is immune at the time the 
HCW was tested, but does not necessarily 
assure that the HCW has long-term immunity. 
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1. Persons known to have had HBV infection in the past or who are chronically infected do not require HBIG or vaccine.  
2. Hepatitis B immune globulin (0.06 mL/kg) administered IM. 
3. Adequate response is anti-HBs of at least 10 mIU/mL after vaccination. 
4. Revaccination = additional 3-dose series of hepatitis B vaccine administered after the primary series. 
5. First dose as soon as possible after exposure and the second dose 1 month later. 
6. Testing should be done as soon as possible after exposure. 
Vaccination and antibody 
response status of exposed  
persons1 
Treatment 
Source is HBsAg positive Source HBsAg negative 
Source is unknown or not tested 
High risk Low risk 
Unvaccinated HBIG2 (1 dose) and begin 
a hepatitis B vaccine series 
Begin a hepatitis B vaccine 
series 
Begin a hepatitis B 
vaccine series 
Begin a hepatitis B 
vaccine series 
Known responder3 No treatment No treatment No treatment No treatment 
Nonresponder3          
Not revaccinated4 HBIG (1 dose) and begin a 
revaccination series 
Begin a revaccination series HBIG (1 dose) and begin a 
revaccination series 
Begin a revaccination 
series 
After revaccination4 HBIG (2 doses)5 No treatment HBIG (2 doses)5 No treatment 
Antibody response unknown 
 
Test for anti-HBs6 
If adequate,3 no treatment 
If inadequate, HBIG x 1 and vaccine 
booster 
 
 
No treatment 
 
Test for anti-HBs6 
If adequate,3 no treatment 
If inadequate, give vaccine booster and check anti-HBs in 
1–2 months 
I'm a nurse who received the hepatitis B 
vaccine series more than 10 years ago and 
had a positive follow-up titer (at least 10 
mIU/mL). At present, my titer is negative 
(less than 10 mIU/mL). What should I do 
now? 
Nothing. Data show that vaccine-induced anti-
HBs levels might decline over time; however, 
immune memory (anamnestic anti-HBs 
response) remains intact indefinitely following 
immunization. Persons with anti-HBs 
concentrations that decline to less than 10 
mIU/mL are still protected against HBV infection. 
For HCWs with normal immune status who have 
demonstrated adequate anti-HBs (at least 10 
mIU/mL) following vaccination, booster doses of 
vaccine or periodic anti-HBs testing is not 
recommended. 
Table 1:  Recommendations of post-exposure prophylaxis after percutaneous or mucosal ex-
posure to HBV in an occupational setting  
Hepatitis B and the Health Care Worker, continued 
